Opus Genetics (NASDAQ:IRD) Rating Increased to Hold at Zacks Research

Key Points

• Zacks Research upgraded Opus Genetics from “strong sell” to “hold,” while the broader analyst consensus remains “Moderate Buy” with a $10.69 price target.
• The stock opened at $3.76 after falling 3.1%; although Opus beat quarterly EPS estimates with a loss of $0.14, revenue of $0.76 million was well below the $2.63 million consensus.
• Insider selling remains notable: insiders sold 1.73 million shares worth approximately $7.48 million over the past 90 days, while institutional investors own 14.97% of the company.

Opus Genetics (NASDAQ:IRD - Get Free Report) was upgraded by investment analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a report released on Tuesday,Zacks.com reports.

A number of other equities research analysts have also issued reports on the stock. B. Riley Financial reaffirmed a "buy" rating on shares of Opus Genetics in a report on Thursday, April 30th. Wall Street Zen raised shares of Opus Genetics from a "strong sell" rating to a "sell" rating in a report on Saturday, August 8th. BTIG Research restated a "buy" rating and set a $12.00 target price on shares of Opus Genetics in a research report on Monday, July 6th. Citigroup initiated coverage on shares of Opus Genetics in a research note on Tuesday, April 28th. They set an "outperform" rating for the company. Finally, Leerink Partners assumed coverage on shares of Opus Genetics in a research note on Thursday, May 21st. They issued an "outperform" rating and a $10.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $10.69.

Opus Genetics Trading Down 3.1%

Opus Genetics stock opened at $3.76 on Tuesday. The firm has a market capitalization of $310.76 million, a price-to-earnings ratio of -2.79 and a beta of 0.59. Opus Genetics has a 12-month low of $1.04 and a 12-month high of $5.81. The firm has a 50 day moving average of $3.79 and a 200 day moving average of $4.15.

Opus Genetics (NASDAQ:IRD - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02. Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 1,091.82%.The firm had revenue of $0.76 million during the quarter, compared to analyst estimates of $2.63 million. On average, analysts predict that Opus Genetics will post -1.05 EPS for the current year.

Insider Activity at Opus Genetics

In related news, Director Fighting Blindness Foundation sold 1,700,000 shares of the firm's stock in a transaction on Monday, May 18th. The shares were sold at an average price of $4.35, for a total value of $7,395,000.00. Following the completion of the transaction, the director directly owned 3,792,171 shares of the company's stock, valued at approximately $16,495,943.85. This trade represents a 30.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO George Magrath sold 9,475 shares of the business's stock in a transaction on Thursday, July 23rd. The stock was sold at an average price of $2.95, for a total transaction of $27,951.25. Following the completion of the sale, the chief executive officer owned 1,731,869 shares in the company, valued at $5,109,013.55. This represents a 0.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 1,729,331 shares of company stock worth $7,481,629 over the last ninety days. Insiders own 11.70% of the company's stock.

Institutional Investors Weigh In On Opus Genetics

Large investors have recently added to or reduced their stakes in the stock. Comerica Bank purchased a new stake in Opus Genetics during the first quarter valued at approximately $29,000. Royal Bank of Canada purchased a new position in shares of Opus Genetics during the 1st quarter worth about $299,000. Nantahala Capital Management LLC boosted its stake in shares of Opus Genetics by 6.0% during the 2nd quarter. Nantahala Capital Management LLC now owns 3,345,923 shares of the company's stock worth $3,152,000 after purchasing an additional 188,028 shares during the period. Mink Brook Asset Management LLC grew its holdings in Opus Genetics by 47.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 1,197,616 shares of the company's stock valued at $1,128,000 after purchasing an additional 387,536 shares during the last quarter. Finally, Opaleye Management Inc. lifted its stake in Opus Genetics by 3.8% in the second quarter. Opaleye Management Inc. now owns 1,220,000 shares of the company's stock worth $1,149,000 after purchasing an additional 45,000 shares during the last quarter. 14.97% of the stock is owned by institutional investors.

Key Opus Genetics News

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Analysts raised earnings estimates: Brookline Capital Markets lifted its projections for Q3 2026 EPS to $(0.15) from $(0.18), FY2026 EPS to $(0.87) from $(1.31), FY2027 EPS to $(0.56) from $(0.77), and FY2028 EPS to $(0.61) from $(0.68). These revisions indicate expectations for narrower losses. Opus Genetics analyst estimates
• Positive Sentiment: HC Wainwright remains bullish: The firm raised its Q4 2026 EPS forecast to $(0.09) from $(0.14), increased its FY2026 estimate to $(1.03) from $(1.18), and raised FY2027 expectations to $(0.40) from $(0.46). It maintains a Buy rating and an $8 price target, well above the stock’s recent trading level.
• Positive Sentiment: Long-term profitability is projected: HC Wainwright forecasts positive EPS of $0.05 in FY2029 and $0.27 in FY2030, while Brookline projects $0.62 in FY2030. These estimates support a potential long-term recovery if Opus successfully advances its pipeline and controls spending.
• Neutral Sentiment: Short-interest data provides little signal: Reported short interest was zero shares with a zero-day days-to-cover ratio, suggesting the data is incomplete or unreliable rather than indicating meaningful investor positioning.
• Negative Sentiment: Losses remain substantial: Analysts still expect Opus Genetics to post a full-year loss of approximately $(1.05) to $(1.09) per share. The latest quarter also showed very low revenue of $0.76 million versus a $2.63 million consensus estimate, despite a modest EPS beat.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source